Nivolumab Immunotherapy-Related Skin Reactions Detected on 18F-FDG PET/CT in Renal Cell Cancer

Clin Nucl Med. 2022 Jul 1;47(7):e513-e514. doi: 10.1097/RLU.0000000000004224. Epub 2022 Apr 20.


Nivolumab, a fully human immunoglobulin G4 anti-programmed cell death 1 antibody, provides a novel therapy option for patients with metastatic cancers. Immunotherapy agents have been associated with immune-related adverse events (irAEs), which may be detected on 18F-FDG PET/CT. Cutaneous toxicities are one of the most common irAEs in the form of maculopapular rash (eczema-like spongiotic dermatitis) and pruritus. These irAEs may lead to false-positive findings on PET/CT done during the treatment. One should be aware of the potential irAEs while interpreting PET/CT to avoid misinterpretation.

MeSH terms

  • Antineoplastic Agents, Immunological*
  • Carcinoma, Renal Cell*
  • Fluorodeoxyglucose F18
  • Humans
  • Immunotherapy / adverse effects
  • Kidney Neoplasms*
  • Nivolumab / adverse effects
  • Positron Emission Tomography Computed Tomography
  • Programmed Cell Death 1 Receptor


  • Antineoplastic Agents, Immunological
  • Programmed Cell Death 1 Receptor
  • Fluorodeoxyglucose F18
  • Nivolumab